 | Up a level |
Thunnissen, E., Lissenberg-Witte, B., Van den Heuvel, M., Monkhorst, K., Skov, B., Sorensen, J., Mellemgaard, A., Dingemans, A., Speel, E., De langen, J., Hashemi, S., Bahce, I., Van Der Drift, M., Buettner, R., Salomon, M. Looijen, Gosney, J., Postmus, P. E., Samii, S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Oz, B., Akyurek, N., Wolf, J., Bubendorf, L., Hiemstra, A., Duin, S., Marondel, L., Timens, W., Schuuring, E., Pauwels, P. and Smit, E. (2018). Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative. J. Thorac. Oncol., 13 (10). S. S452 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Thunnissen, E., Lissenberg-Witte, B., I, van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I, van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I, Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. and Smit, E. F. (2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 138. S. 13 - 19. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332